Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its PTX-100 therapy to treat T-cell lymphomas, a group of aggressive…

Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it builds out an expanded clinical study in 2022. Leading ASX…

Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in treating aggressive rare blood cancers where the company says there…

Cancer results from the mutation of normal cells to tumour cells because of interaction between a person’s genetic factors and carcinogens. As per the Australian…

Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the financial year, its reports show….

ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards its clinical and development milestones. The results announced by the…

Investors have plenty of exciting updates to look forward as PTX advances clinical trials and its world-leading OmniCAR research platform. Clinical stage oncology company Prescient Therapeutics…

Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech Fund (MBF). I say auspiciously as the Small Ordinaries Index…

New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use of next generation cell therapy platform OmniCAR, which harnesses a…

Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of cancer treatments? The latest research out of the journal Nature…